Fig. 1

Clinical course of case 1 after admission to the intensive care unit (ICU). The patient had severe renal dysfunction; therefore, blood purification was initiated immediately. On day 11 after ICU admission, the patient received CHOP therapy. Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) was initiated prophylactically to prevent the exacerbation of tumor lysis syndrome (TLS). To maintain therapeutic blood concentrations of anticancer agents, we initiated SHEDD-fA 6 h after administration of the agents, followed by continuous hemofiltration (CHF). There were no complications related to TLS. On day 21 after ICU admission, the patient was administered rituximab with no complications. Renal function recovered fully, and he was discharged from the ICU on day 23 after ICU admission